{"extraction_ratio": 0.89, "to_compare": [{"generated": ["complete normalization", "progressive mobilization"], "gold": []}, {"generated": ["fourth course"], "gold": []}, {"generated": ["May 2009"], "gold": []}, {"generated": ["16"], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["prolonged life expectancy", "increased number and types of chemotherapeutic drugs"], "gold": []}, {"generated": ["patient"], "gold": []}, {"generated": ["health risks", "complexity"], "gold": []}, {"generated": ["chronic back pain"], "gold": []}, {"generated": ["low dopamine concentrations", "movement control"], "gold": []}, {"generated": ["pharmacokinetic", "pharmacogenomic", "pharmacodynamic"], "gold": []}, {"generated": ["chronic neck, back, and shoulder pain", "past medical history"], "gold": []}, {"generated": ["early in the morning"], "gold": []}, {"generated": ["additional medication"], "gold": []}, {"generated": ["numerous ages found in text"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["genotype for COMT Met/Met", "patient\u2019s PGx results (Table 1)"], "gold": []}, {"generated": ["one out of five"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["past two decades"], "gold": []}, {"generated": ["2009-2010"], "gold": []}, {"generated": ["South Korean population", "83%", "29%"], "gold": []}, {"generated": ["very narrow therapeutic indices"], "gold": []}, {"generated": ["an increasing number of studies"], "gold": []}, {"generated": ["clinic", "important", "studies"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["rs1142345"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["last decade"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["about 70%"], "gold": []}, {"generated": ["CYP1A2", "CYP2C9", "potential interaction", "CYP2C19"], "gold": []}, {"generated": ["time course", "non-targeted approach", "metabolites", "K A"], "gold": []}, {"generated": ["bioavailable concentration", "intestinal absorption", "weight of original starting material", "bioavailability", "plasma concentration", "weight extracted powdered material"], "gold": []}, {"generated": ["public interest", "tremendous surge"], "gold": []}, {"generated": ["chronically"], "gold": []}, {"generated": ["indigenous mode of extraction"], "gold": []}, {"generated": ["44"], "gold": []}, {"generated": ["serial dilutions", "mixture of regeneration system", "UPLC system", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "Waters micromass", "vacuum degasser", "autosampler", "binary pump", "Acquity BEH C18 column", "column oven"], "gold": []}, {"generated": ["almost all"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["vivo", "clinical pharmacokinetic profile"], "gold": []}, {"generated": ["increasing"], "gold": []}, {"generated": ["31%"], "gold": []}, {"generated": ["1985", "1, 20, 6, 14%", "96 h after dose"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["day before", "2 days after"], "gold": []}, {"generated": ["2003"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["1 : 40", "1 : 80"], "gold": []}, {"generated": ["mild cholangiolar proliferation", "chronic hepatitis", "moderate plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis"], "gold": []}, {"generated": ["Tables 1, 2, and 3", "Case 1", "clinicopathological features"], "gold": []}, {"generated": ["lower extremity edema", "initially asymptomatic", "fatigue", "right upper quadrant abdominal pain"], "gold": []}, {"generated": ["vasomotor symptoms of menopause"], "gold": []}, {"generated": ["discontinuation of the herbal supplement"], "gold": []}, {"generated": ["metabolite", "drug", "hapten", "autoimmune response", "immunogen", "host cellular protein", "immune mechanism"], "gold": []}, {"generated": ["Adults"], "gold": []}, {"generated": ["case studies", "similarities", "differences", "published cases", "black cohosh hepatotoxicity"], "gold": []}, {"generated": ["third-generation fluoroquinolone antibiotic family"], "gold": []}, {"generated": ["urinary system infection"], "gold": []}, {"generated": ["pharmacokinetic features", "in vivo distribution studies"], "gold": []}, {"generated": ["rat tissue homogenate"], "gold": []}, {"generated": ["42 mg kg"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["\u00b115%", "acceptable limit"], "gold": []}, {"generated": ["entrance of LVFX", "distribution rate in the tissue"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pharmacokinetic interactions", "pharmacodynamic interactions"], "gold": []}, {"generated": ["2017"], "gold": []}, {"generated": ["people with diabetes"], "gold": []}, {"generated": ["anti-osteoporosis", "anticancer", "antioxidant", "anti-inflammatory"], "gold": []}, {"generated": ["Hanks balanced salt solution (HBSS)", "Minimal Essential Medium (MEM)", "Penicillin-streptomycin", "Trypsin EDTA", "Sodium Pyruvate", "HEPES"], "gold": []}, {"generated": ["No ages found in text"], "gold": []}, {"generated": ["2011"], "gold": []}, {"generated": ["2006"], "gold": []}, {"generated": ["P < 0.05", "P < 0.001", "P < 0.01"], "gold": []}, {"generated": ["hypocholesterolemic drugs", "hypoglycemic drugs"], "gold": []}, {"generated": ["global increase in the prevalence of diabetes and obesity"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["CYP2C8", "CYP2C9", "CYP3A4"], "gold": []}, {"generated": ["DMSO", "acetonitrile", "methanol"], "gold": []}, {"generated": ["30 min"], "gold": []}, {"generated": ["15%\u201320%"], "gold": []}, {"generated": ["10 mg/mL"], "gold": []}, {"generated": ["positive CYP2C9 inhibitor", "positive CYP3A4 inhibitor", "positive CYP2C8 inhibitor"], "gold": []}, {"generated": ["in vitro", "drugs metabolized by CYP2C8", "CYP3A4"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["well tolerated", "all participants"], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["eight"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Subsequently"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["docetaxel AUC0\u2013\u221e"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["midazolam studies"], "gold": []}, {"generated": ["different parts of E. purpurea plants", "leaves", "roots"], "gold": []}, {"generated": ["gene reporter assay", "LS180 cells", "CYP3A4 induction potential", "alkylamides", "E. purpurea extracts"], "gold": []}, {"generated": ["pharmacokinetics of docetaxel"], "gold": []}, {"generated": ["cancer patients"], "gold": []}, {"generated": ["advanced cancer"], "gold": []}, {"generated": ["product dependent"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["10 \u00b5L ethyl gallate", "100 \u00b5L plasma"], "gold": []}, {"generated": ["199.00", "151.00", "139.00", "307.20", "127.03", "443.10", "291.20", "123.00"], "gold": []}, {"generated": ["0.1", "500 ng/mL", "EGCG", "EGC", "50 ng/mL", "EC", "ECG"], "gold": []}, {"generated": ["200 \u00b5L"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Sixteen"], "gold": []}, {"generated": ["no specific age mentioned", "adults", "mild", "children", "adolescents"], "gold": []}, {"generated": ["Day 15", "Day 1"], "gold": []}, {"generated": ["digoxin alone treatment", "AUC", "Day 1"], "gold": []}, {"generated": ["systemic exposure", "study", "reduced"], "gold": []}, {"generated": ["start of the study", "mean \u00b1 SD", "ratios"], "gold": []}, {"generated": ["control group", "repeated administration group"], "gold": []}, {"generated": ["1 or 2 weeks", "plasma concentrations", "rats", "ginsenosides", "RGE"], "gold": []}, {"generated": ["rats"], "gold": []}, {"generated": ["rat plasma"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["rheumatoid arthritis"], "gold": []}, {"generated": ["rheumatoid arthritis"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["Seoul, Korea"], "gold": []}, {"generated": ["100 mg", "liver samples"], "gold": []}, {"generated": ["2 h"], "gold": []}, {"generated": ["Red ginseng extract"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["RGE"], "gold": []}, {"generated": ["2016"], "gold": []}, {"generated": ["2014"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["3.5 \u03bcm"], "gold": []}, {"generated": ["3500", "10", "-40"], "gold": []}, {"generated": ["Rat liver microsomes"], "gold": []}, {"generated": ["half-life"], "gold": []}, {"generated": ["highest recovery"], "gold": []}, {"generated": ["six different rats"], "gold": []}, {"generated": ["ng/mL", "500", "1"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["large individual differences"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["studies", "combinations", "reports"], "gold": []}, {"generated": ["patients with renal dysfunction", "neonates"], "gold": []}, {"generated": ["our analysis of the literature"], "gold": []}, {"generated": ["control rats", "experimental rats"], "gold": []}, {"generated": ["Experiments in mice"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["rats", "digoxin-induced arrhythmias"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["limited research"], "gold": []}, {"generated": ["complex"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["potential for herb-drug interactions"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["two or more drugs", "systemic levels"], "gold": []}, {"generated": ["none"], "gold": []}, {"generated": ["proper drug disposition"], "gold": []}, {"generated": ["C. asiatica"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["0.1% (v/v)"], "gold": []}, {"generated": ["ambient temperature"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["means \u00b1 S.D."], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Prism 8.0.2"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["standard deviation (S.D.)", "mean"], "gold": []}, {"generated": ["standard deviation (S.D.)", "mean"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["data not shown"], "gold": []}, {"generated": ["2003", "2006", "1996", "2012", "2017", "2002", "3", "2011"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["triplicate"], "gold": []}, {"generated": ["CYP2C9", "human liver microsomes", "CYP2C19", "human P450 forms", "CYP3A4", "CYP2D6"], "gold": []}, {"generated": ["plasma concentrations", "CAW-R61J", "clinical studies"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["phase II"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["chronic kidney disease"], "gold": []}, {"generated": ["Each sample"], "gold": []}, {"generated": ["high concentrations", "low concentrations", "medium concentrations"], "gold": []}, {"generated": ["1 ng/mL", "berberine (IS)", "150 \u03bcL"], "gold": []}, {"generated": ["6 \u00b0C", "24 h"], "gold": []}, {"generated": ["10% DMSO", "5 mg/kg", "3 mg/kg"], "gold": []}, {"generated": ["jejunal segments"], "gold": []}, {"generated": ["1 ng/mL", "50 \u03bcL", "150 \u03bcL"], "gold": []}, {"generated": ["previously published reports", "authentic standards", "product ion scan results"], "gold": []}, {"generated": ["1 h after", "rat plasma samples"], "gold": []}, {"generated": ["85", "115"], "gold": []}, {"generated": ["hypertension"], "gold": []}, {"generated": ["adults", "ages", "reported", "mass fragmentation patterns", "product ion mass spectra"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["experiments", "CV", "mean"], "gold": []}, {"generated": ["chronic"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["developing countries"], "gold": []}, {"generated": ["most diseases"], "gold": []}, {"generated": ["26"], "gold": []}, {"generated": ["bioavailable concentration", "intestinal absorption", "plasma concentrations", "soluble extract", "test compound", "GI tract"], "gold": []}, {"generated": ["mg\u00b7kg"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["concentration-dependent inhibition"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["24 h", "72 h"], "gold": []}, {"generated": ["Ambroise Wonkam", "Kevin Dzobo", "Denis Chopera", "Dee Blackhurst", "Michelle Skelton"], "gold": []}, {"generated": ["final manuscript"], "gold": []}, {"generated": ["five major ingredients"], "gold": []}, {"generated": ["7 \u00b1 1-day washout period", "three treatments"], "gold": []}, {"generated": ["our study"], "gold": []}, {"generated": ["1000 mg \u00d7 4 times", "1000 mg", "8 tablets"], "gold": []}, {"generated": ["1000 mg once daily", "1000 mg \u00d7 4 times daily"], "gold": []}, {"generated": ["7680 mg", "1000 mg"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pharmacokinetic (PK) parameters"], "gold": []}, {"generated": ["elderly subjects"], "gold": []}, {"generated": ["greater than 65 years of age"], "gold": ["greater than 65 years of age"]}, {"generated": ["elderly"], "gold": []}, {"generated": ["five days"], "gold": []}, {"generated": ["retention times", "ultraviolet absorption spectra"], "gold": []}, {"generated": ["45"], "gold": []}, {"generated": ["postsupplementation", "presupplementation"], "gold": []}, {"generated": ["17"], "gold": []}, {"generated": ["young individuals"], "gold": []}, {"generated": ["54"], "gold": []}, {"generated": ["42"], "gold": []}, {"generated": ["elderly"], "gold": []}, {"generated": ["various ages found in text"], "gold": []}, {"generated": ["18"], "gold": []}, {"generated": ["specific CYP isoforms", "little effect"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["conventional medications"], "gold": []}, {"generated": ["plasma quinine", "3-hydroxyquinine", "HPLC method"], "gold": []}, {"generated": ["7", "11", "9", "10", "8", "6"], "gold": []}, {"generated": ["breastfeeding", "histories of hypersensitivity to quinine or similar agents", "pregnancy", "adverse side effects from taking G. kola seeds"], "gold": []}, {"generated": ["written informed consent", "certified healthy"], "gold": []}, {"generated": ["600 mg quinine sulphate tablets", "overnight fast"], "gold": []}, {"generated": ["1, 2, 3, 4, 6, 8, 12, 24, 36, 48 h"], "gold": []}, {"generated": ["0.37\u00b5g/ml", "0.5\u00b5g/ml"], "gold": []}, {"generated": ["0\u2013\u221e"], "gold": []}, {"generated": ["very light dizziness"], "gold": []}, {"generated": ["38"], "gold": []}, {"generated": ["CL/F", "T1/2"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["77"], "gold": []}, {"generated": ["KwaZulu-Natal", "adults", "worldwide"], "gold": []}, {"generated": ["1200 mg"], "gold": []}, {"generated": ["both arms", "corrected QT interval (QTc)", "PR interval", "QRS duration", "serial electrocardiograms"], "gold": []}, {"generated": ["ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["data", "prevalence", "percent", "occurrence"], "gold": []}, {"generated": ["increasing incidence", "chronic kidney disease (CKD)"], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["patients' age"], "gold": []}, {"generated": ["20\u201360 years"], "gold": ["20\u201360 years"]}, {"generated": ["13.23%"], "gold": []}, {"generated": ["50\u201370 years"], "gold": ["50\u201370 years"]}, {"generated": ["middle-aged (50\u201364)"], "gold": ["50\u201364"]}, {"generated": [], "gold": []}, {"generated": ["27"], "gold": []}, {"generated": ["90%"], "gold": []}, {"generated": ["18 F", "2 months"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["6 min", "0.5 mL"], "gold": []}, {"generated": ["each blood sampling time"], "gold": []}, {"generated": ["known factor activity", "clotting time", "standard human plasma"], "gold": []}, {"generated": ["CL/kel", "dose", "apparent clearance (CL/F)", "AUC0-\u221e", "half-life", "ln 2/kel", "apparent volume of distribution (V/F)"], "gold": []}, {"generated": ["INR data", "percentage of prothrombin complex activity (PCA)", "S-warfarin concentration-time data", "two-compartment pharmacokinetic model"], "gold": []}, {"generated": ["data not shown"], "gold": []}, {"generated": ["63.0 (57.3\u201368.8)", "60.3 (54.5\u201366.1)", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "1.4 (1.1\u20131.6)", "1.04 (0.94\u20131.67)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.9 (1.1\u20132.7)", "NA", "65.5 (55.3\u201375.6)", "0.010 (0.007\u20130.014)", "0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "1.9 (1.5\u20132.2)", "1.8 (1.7\u20131.9)", "0.94 (0.67\u20131.47)"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2007"], "gold": []}, {"generated": ["7 patients"], "gold": []}, {"generated": ["2007"], "gold": []}, {"generated": ["common", "adults", "patients"], "gold": []}, {"generated": ["recent", "information websites", "popular publications", "directed to cancer patients"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["elderly"], "gold": []}, {"generated": ["600 mg"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["results", "studies", "data", "conclusions"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["36"], "gold": []}, {"generated": ["14 subsequent days"], "gold": []}, {"generated": ["hydroxychlorzoxazone/chlorzoxazone serum ratio", "debrisoquine urinary recovery ratio", "1-hydroxymidazolam/midazolam serum ratio", "paraxanthine/caffeine serum ratio"], "gold": []}, {"generated": ["12 weeks", "15 days"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["two case reports"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["essential", "clinical risks"], "gold": []}, {"generated": ["in vitro", "in vivo"], "gold": []}, {"generated": ["valid clinical observations", "relevant risk"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["P-gp", "UGT", "CYP-isoenzymes"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["7 days"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["regression of the radiological abnormalities", "normalization of the LVEF", "rapid improvement"], "gold": []}, {"generated": ["drug-induced cardiopulmonary toxicity"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["probably associated with venlafaxine"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["metaboliza\u00e7\u00e3o lenta", "circunstancial"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["maioria"], "gold": []}, {"generated": ["35 anos de idade"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["menopausal symptoms"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["date of disappearance", "degree of adverse reaction", "date of onset", "result of adverse reaction"], "gold": []}, {"generated": ["ages", "statistically significant difference", "demographic information"], "gold": []}, {"generated": ["Fisher's exact test", "p-value"], "gold": []}, {"generated": ["fully recovered"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["large-scale", "long period"], "gold": []}, {"generated": ["UGT2B7", "UGT1A1"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["vertical axis", "intersection", "Dixon", "Lineweaver-Burk plots", "second quadrant"], "gold": []}, {"generated": ["0.49 \u03bcM"], "gold": []}, {"generated": ["120-fold", "13-fold"], "gold": []}, {"generated": ["many drugs"], "gold": []}, {"generated": ["previous"], "gold": []}, {"generated": ["AGE: Not specified"], "gold": []}, {"generated": ["chronic liver disease"], "gold": []}, {"generated": ["0.5\u20132.0 g/kg"], "gold": []}, {"generated": ["rats", "human"], "gold": []}, {"generated": ["repeated administration", "high dose", "Rc", "RGE", "valsartan"], "gold": []}, {"generated": ["0.1\u20130.2%", "34.1 \u03bcM", "7.8 \u03bcM", "0.4\u20130.5%"], "gold": []}, {"generated": ["16,000\u00d7 g", "50 \u03bcL", "10 min", "\u221280 \u00b0C"], "gold": []}, {"generated": ["1.5", "48", "4", "0.33", "0.67", "8", "24", "2", "0.17"], "gold": []}, {"generated": ["1-week"], "gold": []}, {"generated": ["0 to 48 h"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["\u00b11 day"], "gold": []}, {"generated": ["24 subjects"], "gold": []}, {"generated": ["malondialdehyde (MDA)"], "gold": []}, {"generated": ["disease of antioxidant deficiency"], "gold": []}, {"generated": ["markedly"], "gold": []}, {"generated": ["OS"], "gold": []}, {"generated": ["C. sinensis"], "gold": []}, {"generated": ["120 g", "200 \u00b5L", "1 mL", "4 h", "4 \u00b0C"], "gold": []}, {"generated": ["0.54\u20131,32 pg/mL", "1,1\u2032,3,3\u2032-tetramethoxypropane"], "gold": []}, {"generated": ["described"], "gold": []}, {"generated": ["25", "75"], "gold": []}, {"generated": ["group 1", "group 2", "group 3"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pancreatic \u03b2 cells", "FBS level"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["insulin tolerance", "significant reduction", "glucose levels"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["proliferative and secretory phases", "longer follow-up"], "gold": []}, {"generated": ["patients"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["2006", "20"], "gold": []}, {"generated": ["V05895B"], "gold": []}, {"generated": ["days 0, 14, and 28"], "gold": []}, {"generated": ["treatment", "confidence intervals", "analysis of variance model", "natural log transformed"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["<50 copies/ml"], "gold": []}, {"generated": ["Darunavir"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["clinical pharmacokinetic interactions", "botanicals", "antiretroviral agents"], "gold": []}, {"generated": ["darunavir pharmacokinetics", "variability"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no relevant effect on the in vivo activity of the major CYP enzymes in humans"], "gold": []}, {"generated": ["variety of disorders"], "gold": []}, {"generated": ["8 days"], "gold": []}, {"generated": ["precipitation", "MID assays", "DEX", "DOR", "OME", "5-OH-OME", "internal standard"], "gold": []}, {"generated": ["standard bioequivalence approach"], "gold": []}, {"generated": ["120"], "gold": []}, {"generated": ["240-mg EGb 761\u00ae daily dose", "1 week"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["8-day period"], "gold": []}, {"generated": ["pharmacodynamic (PD)", "pharmacokinetic (PK)", "randomized controlled trials"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["standard eligibility inclusion criteria"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["29", "21", "24", "26", "28"], "gold": []}, {"generated": ["high risk of bias", "minus (-) marked circle", "unclear risk of bias", "minimum age"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["different ages found in text"], "gold": []}, {"generated": ["potential herb-warfarin interaction"], "gold": []}, {"generated": ["multiple reasons"], "gold": []}, {"generated": ["in vivo study", "drugs metabolized by CYP2C9"], "gold": []}, {"generated": ["in vivo study", "48", "hepatic damage", "dose-dependent manner"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no history of warfarin use", "detected in her blood serum analysis"], "gold": []}, {"generated": ["greater than seven", "more than 37 seconds", "more than 70 seconds"], "gold": []}, {"generated": ["unknown DIC", "unknown pathologic inhibitors", "unknown coagulopathy", "unknown origin", "unknown vitamin K malabsorption"], "gold": []}, {"generated": ["study protocol", "subject enrollment"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": ["in vitro inhibitory potency", "well\u2010characterized composition", "human pharmacokinetic data"], "gold": []}, {"generated": ["raloxifene", "silibinin predosing", "multiple dosing", "alternate study designs"], "gold": []}, {"generated": ["oxidative metabolism", "conjugative metabolism"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["95%"], "gold": []}, {"generated": ["12-hour", "4-hour", "6-hour", "3-hour", "8-hour", "10-hour"], "gold": []}, {"generated": ["curcumin"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["comprehensive systematic review", "existing literature"], "gold": []}, {"generated": ["2012"], "gold": []}, {"generated": ["2012"], "gold": []}, {"generated": ["rabbits", "human"], "gold": []}, {"generated": ["two children", "rats"], "gold": []}, {"generated": ["long-term basis"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["reduced the plasma level of CBZ"], "gold": []}, {"generated": ["Caution"], "gold": []}, {"generated": ["patients with major depression or bipolar disorder"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["proactive monitoring"], "gold": []}, {"generated": ["variables", "significant relationship", "p < 0.05"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["that age group", "highest number of patients with type-2 diabetes"], "gold": []}, {"generated": ["hypoglycaemic agents", "patients", "Tabular summary", "pharmacological management"], "gold": []}, {"generated": ["12 identified plants"], "gold": []}, {"generated": ["patients with diabetes"], "gold": []}, {"generated": [], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["thousands of years"], "gold": []}, {"generated": ["hepatocellular carcinoma"], "gold": []}, {"generated": ["15 min"], "gold": []}, {"generated": ["22 compounds"], "gold": []}, {"generated": ["150 \u00b5g/mL", "68 \u00b5g/mL"], "gold": []}, {"generated": ["human"], "gold": []}, {"generated": ["Ultimate 3000 UPLC system", "UPLC-MS/MS analysis", "LTQ-Orbitrap Elite mass spectrometer", "notoginsenoside R"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2 \u00d7 10 Total RNA"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["whole experiments"], "gold": []}, {"generated": ["p < 0.01", "p < 0.001"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["drug transporters", "cytochrome P450 enzymes", "CYPs"], "gold": []}, {"generated": ["L-MDR1 cells", "human P-glycoprotein (P-gp)"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["minor effect"], "gold": []}, {"generated": ["in vitro"], "gold": []}, {"generated": ["concomitantly used drugs"], "gold": []}, {"generated": ["MDCKII-BCRP cells", "parental cell line MDCKII"], "gold": []}, {"generated": ["positively controls", "published previously"], "gold": []}, {"generated": ["1%", "Banderol", "Samento"], "gold": []}, {"generated": ["RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit", "miniprep Kit"], "gold": []}, {"generated": ["previous"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Reporter gene assays"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["four days"], "gold": []}, {"generated": ["LS180 cells"], "gold": []}, {"generated": ["t = 0"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["original formulation"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2 weeks"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["throughout the study"], "gold": []}, {"generated": ["500\u00b0C", "5500 V"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["0,\u221e"], "gold": []}, {"generated": ["90% confidence intervals"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["different types of statins"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["65.38%", "69.90%"], "gold": []}, {"generated": ["Figure 5A,B"], "gold": []}, {"generated": ["66.77%", "41.06%"], "gold": []}, {"generated": ["pharmacokinetic disposition"], "gold": []}, {"generated": ["determine", "pharmacokinetic interaction", "DAS"], "gold": []}, {"generated": ["DAS 25 mg/kg"], "gold": []}, {"generated": ["12 h", "one week", "12-h"], "gold": []}, {"generated": ["25 mg/kg", "7 days", "Group II", "Group I"], "gold": []}, {"generated": ["7 days", "40 mg/kg", "7th day", "2 hours"], "gold": []}, {"generated": ["positive direction", "electrospray ionization"], "gold": []}, {"generated": ["humans", "in vivo studies"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["KSU-SE-21-58"], "gold": []}, {"generated": ["age group", "subject age", "standard deviation", "patient age", "mean age", "sample age", "average age", "age range"], "gold": []}, {"generated": ["APG pretreatment", "rats", "DAS administration"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["population", "herb-mediated changes"], "gold": []}, {"generated": ["elderly"], "gold": []}, {"generated": ["adult women"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["26", "27"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["\u221280 \u00b0C"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["height, weight, or BMI at baseline"], "gold": []}, {"generated": ["baseline", "12 weeks"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["about 20 years ago"], "gold": []}, {"generated": ["pregnane-X-receptor"], "gold": []}, {"generated": ["2006", "2017", "2019", "2004", "2009", "2012"], "gold": []}, {"generated": ["potentially relevant targets for depression"], "gold": []}, {"generated": ["time of immobility"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["recently", "2018", "2019"], "gold": []}, {"generated": ["low\u2010hyperforin", "seven test drugs"], "gold": []}, {"generated": ["cancer therapies", "high quality clinical data"], "gold": []}, {"generated": ["Yunzhi", "Lingzhi"], "gold": []}, {"generated": ["significant dosage differences"], "gold": []}, {"generated": ["Figure 1"], "gold": []}, {"generated": ["83", "144", "145", "111", "63", "99", "141", "103", "101", "105", "98", "67", "20", "84"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["tumor cell angiogenesis", "reactive oxygen species production"], "gold": []}, {"generated": ["recent study", "tumor metabolism", "gut dysbiosis induced by paclitaxel"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": ["Multiple ages not specified"], "gold": []}, {"generated": ["clinical settings", "adverse effects", "chemotherapeutic drugs"], "gold": []}, {"generated": ["Table S4"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["described ages found in text"], "gold": []}, {"generated": ["conventional cancer therapy", "frequently"], "gold": []}, {"generated": ["70\u201380%"], "gold": []}, {"generated": ["breast cancer patients", "other types of cancer"], "gold": []}, {"generated": ["306\u2009ng/mL", "5\u2009mg"], "gold": []}, {"generated": ["human liver microsomes", "\u03b2-estradiol", "4-hydroxy-N-desmethyltamoxifen hydrochloride", "HLMs", "dextrorphan-d"], "gold": []}, {"generated": ["concentration-dependent inhibition of proliferation"], "gold": []}, {"generated": ["enzyme phenotypes", "patients", "metabolizers"], "gold": []}, {"generated": ["studies", "long-term outcomes"], "gold": []}, {"generated": ["50 donors"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["0.1", "100", "5", "10", "2", "1"], "gold": []}, {"generated": ["Springer Nature"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["5% ammonia", "30 min", "30 seconds", "180 \u00b5L", "2-4-dibromoacetophenone", "520 ppm"], "gold": []}, {"generated": ["two weeks", "4.5 mg/200 g BW", "morning", "single"], "gold": []}, {"generated": ["anaesthetized"], "gold": []}, {"generated": ["1.0 mL"], "gold": []}, {"generated": ["captopril analysis", "precision", "within-run accuracy"], "gold": []}, {"generated": ["six rats"], "gold": []}, {"generated": ["plasma sulfhydryl groups", "2-4-dibromoacetophenone", "captopril"], "gold": []}, {"generated": ["basic pH"], "gold": []}, {"generated": ["17"], "gold": []}, {"generated": ["Two weeks", "coadministration", "expression of the PEPT1 transporter", "H. sabdariffa extract", "GSH level"], "gold": []}, {"generated": ["2016"], "gold": []}, {"generated": ["2016"], "gold": []}, {"generated": ["laboratory rodent"], "gold": []}, {"generated": ["Agilent 1290 series"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["might occur"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [""], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["anti-diabetic"], "gold": []}, {"generated": ["during the course of his treatment", "probably"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["seven days"], "gold": []}, {"generated": ["filtered", "previous filtrate"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["elderly", "adolescents"], "gold": []}, {"generated": ["0.642min", "0.482min"], "gold": []}, {"generated": ["diabetes", "oxidative stress", "inflammatory response", "liver damage"], "gold": []}, {"generated": ["six rats"], "gold": []}, {"generated": ["diabetic control group", "significantly different from normal group"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["9"], "gold": []}, {"generated": ["diabetic control group", "significantly different from normal group"], "gold": []}, {"generated": ["significant alterations"], "gold": []}, {"generated": ["rats"], "gold": []}, {"generated": ["tissue homogenates", "plasma sample preparation"], "gold": []}, {"generated": ["six rats"], "gold": []}, {"generated": ["0\u20131 h", "1\u20132 h", "5\u20136 h", "6\u20137 h", "3\u20134 h", "2\u20133 h", "4\u20135 h"], "gold": []}, {"generated": ["18\u201328 h", "0\u20136 h", "6\u201318 h"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["indomethacin-induced gastric injury"], "gold": []}, {"generated": ["plasma concentration-time curves", "S-AOE", "indomethacin", "model group", "M-AOE"], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": ["1.7", "2.5", "1.875"], "gold": []}, {"generated": ["moderate intake", "occasionally", "375 ml"], "gold": []}, {"generated": ["no ages found"], "gold": []}, {"generated": ["daily diet"], "gold": []}, {"generated": ["10%"], "gold": []}, {"generated": ["three patients"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["dose dependent manner"], "gold": []}, {"generated": ["high relative quantities"], "gold": []}, {"generated": ["44, 45"], "gold": []}, {"generated": ["7.2"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["15 day"], "gold": []}, {"generated": ["most studies"], "gold": []}, {"generated": ["hypotensive activity", "cyclooxygenase inhibitory activity", "new vessel formation", "reduction of myocardial mass", "ERK pathway", "several potential mechanisms", "anthocyanins", "ACE inhibition", "blood viscosity", "active site", "calcium influx", "PI3-K/Akt pathway", "adipocyte differentiation", "endothelium-derived relaxant pathways"], "gold": []}, {"generated": ["lower doses", "extremely high doses"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["early version", "customers"], "gold": []}, {"generated": ["clinical importance"], "gold": []}, {"generated": ["clinically-relevant dose", "three-fold increase"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["21"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["elderly", "adolescents", "senior citizens"], "gold": []}, {"generated": ["in vitro", "human liver microsomes (HLM)", "potential mechanism\u2010based inhibitors"], "gold": []}, {"generated": ["cooling block", "Selleckchem, Houston, TX, USA"], "gold": []}, {"generated": ["noncompetitive", "competitive", "mixed-inhibition"], "gold": []}, {"generated": ["clinical setting"], "gold": []}, {"generated": ["different tissues"], "gold": []}, {"generated": ["tissue-to-plasma partition coefficients"], "gold": []}, {"generated": ["three lignans"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["72"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["different cancer cell lines"], "gold": []}, {"generated": ["haemorrhage"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Western blot", "Real Time-Polymerase Chain Reaction"], "gold": []}, {"generated": ["pharmacodynamic analysis"], "gold": []}, {"generated": ["2005"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["5 min", "10 min", "30 min", "90 min", "13 min", "12 min"], "gold": []}, {"generated": ["420%"], "gold": []}, {"generated": ["vehicle control group", "doses of Danshen", "mRNA expression level of CYP2C6"], "gold": []}, {"generated": ["P < 0.05", "P < 0.001", "P < 0.01"], "gold": []}, {"generated": ["32", "24"], "gold": []}, {"generated": ["previous study", "rats"], "gold": []}, {"generated": ["taken together with the results of the current study"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["human", "rats", "several different species"], "gold": []}, {"generated": ["warfarin dose"], "gold": []}, {"generated": ["57"], "gold": []}, {"generated": ["warfarin hydroxylation"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["in vitro", "in vivo"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["early stage breast cancer"], "gold": []}, {"generated": ["publication"], "gold": []}, {"generated": ["mean recovery", "88%"], "gold": []}, {"generated": ["extracted ion chromatograms", "interference with drug quantitation"], "gold": []}, {"generated": ["37 months", "4 months", "113 months"], "gold": []}, {"generated": ["Competing interests"], "gold": []}, {"generated": ["chronically ill patients", "patients with terminal diseases"], "gold": []}, {"generated": ["minor ailments", "cancer", "diabetes", "hypertension", "chronic diseases", "antimicrobials", "asthma", "antimalarials", "peptic ulcer"], "gold": []}, {"generated": ["over 70%"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["filtered", "freeze-dried", "concentrated"], "gold": []}, {"generated": ["Darmstadt", "Merck", "LiChrosolv GG", "Germany"], "gold": []}, {"generated": ["2005", "2013", "2007"], "gold": []}, {"generated": ["positive ion mode", "Multiple reaction monitoring (MRM) mode"], "gold": []}, {"generated": ["Fifty percent inhibitory concentration", "concentration of aqueous extract of herb"], "gold": []}, {"generated": ["commonly used herbs"], "gold": []}, {"generated": ["highest dose of the extract", "eight major human CYP isoenzymes", "three of the plants"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["oven\u2010dried Allium sativum bulbs"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Strandell"], "gold": []}, {"generated": ["2000"], "gold": []}, {"generated": ["CYP2C19", "CYP3A4", "CYP1A2"], "gold": []}, {"generated": ["menopause"], "gold": []}, {"generated": ["cognitive declines", "sexual dysfunction", "sleep disturbances", "night sweats", "weight gain", "transition to menopause", "hot flashes", "mood disorders", "problematic symptoms"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no ages mentioned"], "gold": []}, {"generated": ["30 days"], "gold": []}, {"generated": ["14 days", "851"], "gold": []}, {"generated": ["sequentially numbered"], "gold": []}, {"generated": ["simvastatin", "lovastatin", "plasma concentrations", "mean (SD)", "Figure 4", "internal standard", "simvastatin hydroxy acid"], "gold": []}, {"generated": ["mean (SD)"], "gold": []}, {"generated": ["P < 0.05"], "gold": []}, {"generated": ["40 mg"], "gold": []}, {"generated": ["worldwide popularity"], "gold": []}, {"generated": ["65-year-old"], "gold": ["65-year-old"]}, {"generated": ["illnesses"], "gold": []}, {"generated": ["lifestyle", "measures", "possible interactions"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["All subjects"], "gold": []}, {"generated": ["n= 12", "2 weeks"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["previous studies"], "gold": []}, {"generated": ["earlier surveys", "high levels of herb-drug use", "health care professionals"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["herb-drug interactions", "In vitro", "potential", "first stage"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["type 1"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Waters Alliance 2690 HPLC", "High resolution LC-MS", "Waters Micromass Ltd.", "Mass Lynx V4.1 software", "Waters LCT Time of Flight Mass Spectrometer", "HPLC conditions"], "gold": []}, {"generated": ["15"], "gold": []}, {"generated": ["35"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["significantly (p \u2264 0.05)"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["ages found in text"], "gold": []}, {"generated": ["Five days"], "gold": []}, {"generated": ["well-studied treatment"], "gold": []}, {"generated": ["extract", "refractory"], "gold": []}, {"generated": ["selected single herbs", "Wen Bing formulas"], "gold": []}, {"generated": ["1902"], "gold": []}, {"generated": ["as internal standard"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["5 \u03bcL", "600 \u03bcL", "8 mg/mL"], "gold": []}, {"generated": ["8 PM", "Day 5", "30 minutes"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["significantly suppressed", "all the herb/herbal components"], "gold": []}, {"generated": ["teen", "ten marker components"], "gold": []}, {"generated": ["in-vitro experiments", "anti-influenza herbs/herbal components"], "gold": []}, {"generated": ["significantly increase", "decrease"], "gold": []}, {"generated": ["OS ratio", "rat urine samples", "Renal senescence", "OSA", "AGEs", "AGE", "oxidative stress"], "gold": []}, {"generated": ["S8"], "gold": []}, {"generated": ["influenza viruses"], "gold": []}, {"generated": ["rat plasma", "100 \u03bcg/mL", "500 \u03bcg/mL"], "gold": []}, {"generated": ["rat plasma"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["six-dimension in-vitro screening", "metabolic clearance (CL", "ex-vivo pharmacodynamic evaluation", "in-vivo pharmacokinetics in rats", "pop-PK model", "absorption rate (k", "after co-administration", "Table 1", "62%"], "gold": []}, {"generated": ["Root of Isatis indigotica Fort., Banlangen"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pre-clinical studies"], "gold": []}, {"generated": ["all the cancer patients", "breast cancer patients"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["recent study", "MCF7", "T47D", "TAM"], "gold": []}, {"generated": ["T-47D", "MCF-7"], "gold": []}, {"generated": ["many European countries"], "gold": []}, {"generated": ["10 Evn-50", "2012"], "gold": []}, {"generated": ["12 traditional herbs"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2015"], "gold": []}, {"generated": ["sGPT", "liver transaminases", "TAM-intoxicated liver injury", "sGOT", "rats", "glutathione", "TBARS", "antioxidant enzymes", "significant increase"], "gold": []}, {"generated": ["2009"], "gold": []}, {"generated": ["MDR1", "BCRP", "HDI", "PCA", "OAT1/3", "in vitro", "GA"], "gold": []}, {"generated": ["2000\u20132019"], "gold": []}, {"generated": ["prostatitis", "urinary tract infections", "pyelonephritis"], "gold": []}, {"generated": ["pharmacokinetic-based HDIs", "PCA", "tissue distribution-based HDIs", "GA", "PCE"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2006", "2012", "2007", "1990"], "gold": []}, {"generated": ["11.5\u201313.5 min", "8.7\u201311 min", "0\u20138.5 min", "14\u201315 min"], "gold": []}, {"generated": ["quantification"], "gold": []}, {"generated": ["362.2", "318.1", "332.1", "288.1"], "gold": []}, {"generated": ["PK changes of GA and PCA", "co-administration of CIP and PCE", "Figures 3, 4"], "gold": []}, {"generated": ["intragastric administration", "intravenous administration"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["approximately 1%", "approximately 10%"], "gold": []}, {"generated": ["2021ZD030", "2021ZD017", "2018ZX09734-002"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["similar", "laboratory"], "gold": []}, {"generated": ["extremely", "not at all"], "gold": []}, {"generated": ["13.3", "15.00"], "gold": []}, {"generated": ["exercise time (Figure 3)", "treatment (YM vs. PLC)", "Total Energy Expenditure (TEE)"], "gold": []}, {"generated": ["24% increase", "low to moderate exercise intensities"], "gold": []}, {"generated": ["12 weeks"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["active ingredients", "bioavailability"], "gold": []}, {"generated": ["favorable psychomotor effects", "satiety", "mood state"], "gold": []}, {"generated": ["future research", "lower BF% percentile", "longitudinal YM effectiveness", "physically active"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Seoul, Korea"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["ad libitum"], "gold": []}, {"generated": ["Rats"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["various patient demographics"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["CYP450 family", "DMEs"], "gold": []}, {"generated": ["further", "anecdotal", "clinical"], "gold": []}, {"generated": ["symptoms of cognition decline", "anxiety and mood disorders", "cardiovascular disorders", "memory loss", "general well-being", "clinically significant improvement", "fatigue"], "gold": []}, {"generated": ["subtherapeutic"], "gold": []}, {"generated": ["human studies", "midazolam"], "gold": []}, {"generated": ["itself", "chronic use"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["18"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["21"], "gold": []}, {"generated": ["herbal products"], "gold": []}, {"generated": ["different herbal species", "many marketed herbal products"], "gold": []}, {"generated": ["human small intestinal enterocytes"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["drugs", "rich sources", "natural bioactive compounds"], "gold": []}, {"generated": ["kidney transplantation"], "gold": []}, {"generated": ["age found in text"], "gold": []}, {"generated": ["April 2016"], "gold": []}, {"generated": ["74.27"], "gold": []}, {"generated": ["serious adverse effects"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["graft rejection"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [""], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["74.27"], "gold": []}, {"generated": ["possible effect"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["n = 6", "mean \u00b1 S. D."], "gold": []}, {"generated": ["groups 2 and 3", "groups 1 and 2", "statistically significant differences"], "gold": []}, {"generated": ["Zuccotti Park"], "gold": []}, {"generated": ["pretreatment period", "possible herbal drug effect"], "gold": []}, {"generated": ["dryness", "combined", "evaporated"], "gold": []}, {"generated": ["patients", "available", "elderly", "senior citizens"], "gold": []}, {"generated": ["Europe", "practical effects", "regulatory environment"], "gold": []}, {"generated": ["less knowledge"], "gold": []}, {"generated": ["years"], "gold": []}, {"generated": ["most frequently occurring species"], "gold": []}, {"generated": ["56.6%"], "gold": []}, {"generated": ["described in text"], "gold": []}, {"generated": ["two studies"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["safe daily dose"], "gold": []}, {"generated": ["time until surgical intervention", "short-term"], "gold": []}, {"generated": ["500 mg", "2\u20133 days"], "gold": []}, {"generated": ["insufficiently defined product quality"], "gold": []}, {"generated": ["emerging"], "gold": []}, {"generated": ["older adults", "teenagers"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["154"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["2018"], "gold": []}, {"generated": ["more frequently", "these groups"], "gold": []}, {"generated": ["3 weeks"], "gold": []}, {"generated": ["individual genotype", "unusually susceptible"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["human"], "gold": []}, {"generated": ["weekly", "7.5", "28%", "15"], "gold": []}, {"generated": ["individual susceptibility"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["great proportion"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["published maps", "institutional affiliations"], "gold": []}, {"generated": ["variety of ages found in text"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["pharmacodynamic", "HDI"], "gold": []}, {"generated": ["large number of sulfur compounds", "allyl thiosulfinates (mainly allicin)", "bioactive compounds", "allyl thiosulfinates"], "gold": []}, {"generated": ["two millennia"], "gold": []}, {"generated": ["individuals with diabetes"], "gold": []}, {"generated": ["experimental"], "gold": []}, {"generated": ["conventional antidiabetics"], "gold": []}, {"generated": ["98"], "gold": []}, {"generated": ["complex herbal interventions", "more complex interactions", "relevant chemical and pharmacological data"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["Springer Nature"], "gold": []}, {"generated": ["various ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["several studies"], "gold": []}, {"generated": ["USP reference standard"], "gold": []}, {"generated": ["HPLC grade solvents", "HPLC determinations", "General-purpose reagents"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["significant P value \u2a7d0.05"], "gold": []}, {"generated": ["in vitro", "concentration dependent manner"], "gold": []}, {"generated": ["25 \u03bcg/ml"], "gold": []}, {"generated": ["healthy human volunteers"], "gold": []}, {"generated": ["clinical study"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["patients' outcomes", "abemaciclib-related diarrhea", "quality of life"], "gold": []}, {"generated": [], "gold": []}]}